Invitae Corporation (NVTA)

CRISPR Therapeutics may soon generate its first product revenue. Invitae, making progress in its recovery plan, could climb if it meets its goals.

Invitae Corporation (NYSE:NVTA ) Q3 2023 Earnings Conference Call November 8, 2023 4:30 PM ET Company Participants Hoki Luk - VP, IR and Corporate Development Ken Knight - President & CEO Ana Schrank ...

The headline numbers for Invitae (NVTA) give insight into how the company performed in the quarter ended September 2023, but it may be worthwhile to compare some of its key metrics to Wall Street esti...

Invitae's stock is down and it might get delisted from its stock exchange. It has a new crop of top managers, but it's running low on cash.

Invitae's revenue has climbed over time thanks to a vast portfolio of genetic tests. At the same time, the company has struggled to turn that into profitability.

While penny stocks offer high potential gains, they are among the riskiest sub-$5 investments an investor can make. The low stock price penny stocks offer often reflects weak business models, high deb...

- Sponsor of the Heart of Genetic Counseling program and award, recognizing excellence in patient care - - These studies combined with new digital tools aim to increase access and frequency of heredit...

Late Friday, the U.S. FDA granted De Novo marketing authorization for the Invitae Common Hereditary Cancers Panel. The panel is the first of its kind to receive FDA marketing authorization.

Invitae (NYSE: NVTA ) stock is on the rise Monday despite a lack of news from the medical genetics company this morning. There haven't been any new press releases or filings with the Securities and Ex...

The genetic testing company is reducing costs to improve margins.